Leading the Way in Life Science Technologies

GEN Exclusives

More »

May. 15, Vol. 33, No. 10

    • Feature Articles

      • Cancer Diagnostics, Pushing the Boundaries
      • Vicki Glaser
      • Molecular techniques and technologies to probe alterations in gene and protein expression that may contribute to the development, progression, prognosis, heterogeneity, therapeutic options, and drug-resistance of cancers and tumor types are an incre ... more »
      • Improving Proteomics Approaches
      • Angelo DePalma, Ph.D.
      • Proteomics has undergone the same existential choice, and self-examination, as other biological sciences with respect to automation. On the surface, automation helps laboratories cope with very high-throughput workflows. Return on investment can b ... more »
      • Seasoned Drugs Offer Therapeutic Gold Mine
      • Caitlin Smith
      • The process of discovering new drugs is mainly linear—and prone to bottlenecks. Putting a new drug on the pharmacy shelf may take well over a decade, which spells a waste of time and money if the drug fails once it reaches the market. Drug reposit ... more »
    • Tutorials

    • Corporate Profile

      • Softening the Blow from FOLFOX Treatment
      • Just as serendipity wrought the discoveries that Viagra did wonders for sexual dysfunction in men, and Dramamine treated travel sickness better than allergies, so too did it cause a seven-year-old Swedish drug developer to reposition the MRI contras ... more »
    • BioMarket Trends

      • Biotechs Need to Walk the Walk on Drug Value
      • Small- to mid-sized biotechnology companies must retool their R&D strategies to pay as much attention to how private and government insurers or “payers” will value their new drugs as is traditionally paid to making the medicines work, Ernst & ... more »
    • Insight & Intelligence™

      • Crowdfunding Touches Down in Biotech
      • Alex Philippidis
      • A year has passed since President Barack Obama enacted a law intended to spark business growth by encouraging “crowdfunding” of startups. Much of the law remains to be implemented, but that hasn’t stopped crowdfunding sites Poliwogg and Microryza fr ... more »
    • Assay Tutorials

    • Sidebars

      • Highlights from AACR
      • At the 2013 AACR meeting, Stand Up to Cancer (SU2C) formally introduced its alliance with the St. Baldrick’s Foundation and announced the newest SU2C research Dream Team, targeting pediatric cancers. The Dream Team will receive a $14.5 million trans ... more »
    • Corporate Capabilities

      • Advertorial: Agilent Technologies
      • Agilent Technologies (spun off from Hewlett Packard in 1999) maintains a clear focus on analytical measurement and has leveraged its considerable expertise in chemical analysis into the creation of a large portfolio of life science tools. Agilent an ... more »

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »